Biomarkers and Treatment Efficacy in pMMR Endometrial Cancer – ENGOT
ENGOT shared a post on LinkedIn about a paper by Els Van Nieuwenhuysen et al. published in Gynaecological Oncology:
“Suggested reading for the week: A new publication reports exploratory biomarker analyses from the ENGOT-en10/BGOG/GOG-3041/DUO-E Phase III trial in patients with mismatch repair proficient (pMMR) advanced or recurrent endometrial cancer.
The study evaluated carboplatin/paclitaxel plus durvalumab followed by durvalumab with or without olaparib compared with carboplatin/paclitaxel alone. In the pMMR subpopulation, exploratory analyses showed a highly heterogeneous biomarker landscape, with frequent overlap between biomarkers and tumour histologies. Across multiple biomarker and histological subgroups, progression-free survival hazard ratios favoured both durvalumab-containing treatment arms compared with control, with the durvalumab plus olaparib arm favoured in most assessed subgroups.
For patients, these findings add to the evidence that carboplatin/paclitaxel plus durvalumab followed by durvalumab plus olaparib may help delay disease progression in pMMR endometrial cancer, a group in which tumours can be biologically diverse.
The trial was led by The GOG Foundation, Inc with the Belgian Gynaecological Oncology Group as the ENGOT lead group in cooperation with CEEGOG, GEICO – Spanish Gynaecological Cancer Research Group, HeCOG-Hellenic Cooperative Oncology Group, ISGO, NOGGO e.V., NSGO-CTU and PGOG
Prof. Els Van Nieuwenhuysen (BGOG,) has previously presented findings at ESGO 2025 and IGCS 2024. Watch the videos on our website.
Read the paper:
Learn more about the trial.”
Title: Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: exploratory analyses of the DUO-E/GOG-3041/ENGOT-EN10 trial
Authors: Shannon N. Westin, Kathleen Moore, Hye Sook Chon, Jessica Thomes Pepin, Erin A. Salinas, David Starks, Paul A. DiSilvestro, Brian Slomovitz, Elen Vettu, Fernando Gálvez-Montosa, Kofi Agyemang-Prempeh, Flora Zagouri, Jae-Weon Kim, Qinglei Gao, Fernando Contreras Mejia, Andreia Cristina De Melo, Tadaaki Nishikawa, Matthew Kowgier, Sonia Iyer, Ying Wang, Els Van Nieuwenhuysen
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
May 13, 2026, 16:24Shanza Ghaffar: Recurrent Pregnancy Loss Beyond Diagnosis and Treatment
-
May 13, 2026, 16:16Alejandro González: A Historic Moment for the PCOS Community
-
May 13, 2026, 16:15Antonio La Marca: Where There Is Research, There Is Better Care
-
May 13, 2026, 16:06Mirjam Teboe: APS Diagnosis Faces False Positive Challenges in Lupus Anticoagulant Testing
-
May 13, 2026, 16:03The Link Between Lifestyle and Environmental Exposures and Endometriotic Phenotype – RBMO
-
May 13, 2026, 11:42Analysis of MED-12 Mutations in Uterine Leiomyomas of Nigerian Women – Fertility and Sterility
-
May 13, 2026, 11:33Anuja Dokras: SPIRE 2026 Brings Together the Global Fertility Community
-
May 13, 2026, 11:23Sean Lauber: Why Do Aneuploid Embryos Rarely Lead to Live Births?
-
May 13, 2026, 10:40Polyendocrine Metabolic Ovarian Syndrome, the New Name for PCOS – PCOS Awareness Association